Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-018-0635-3
Abstract: BackgroundPixantrone is recommended in relapsed and refractory non-Hodgkin lymphoma (NHL) or heavily pretreated NHL patients. Its conditional approval in Europe was based on results from the open-label, randomized, phase 3 PIX301 study, comparing pixantrone monotherapy… read more here.
Keywords: relapsed refractory; lymphoma; response; long term ... See more keywords
An evaluation of pixantrone for the treatment of non-Hodgkin’s lymphoma
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2018.1528232
Abstract: ABSTRACT Introduction: The overall prognosis for patients with relapsed or refractory aggressive non-Hodgkin’s lymphomas is poor. Only a minority of patients are able to receive autologous stem cell transplantation. Patients not transplant-eligible or patients relapsing… read more here.
Keywords: lymphoma; treatment; non hodgkin; pixantrone ... See more keywords
Another disappointment in treating relapsed, refractory high‐risk aggressive B‐cell lymphomas
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.16259
Abstract: Optimising outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) remains one of the greatest challenges still facing haemato-oncologists today. The SCHOLAR-1 analysis pooled trial and retrospective data (n = 636) and… read more here.
Keywords: relapsed refractory; trial; aggressive cell; pixantrone ... See more keywords
Long-term efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma achieving a complete response with pixantrone.
Sign Up to like & getrecommendations! Published in 2023 at "European journal of haematology"
DOI: 10.1111/ejh.13989
Abstract: INTRODUCTION The prognosis of diffuse large B-cell lymphoma (DLBCL) patients with refractory or multiply relapsed (R/R) disease is disappointing. Pixantrone is currently approved as third or fourth line regimen, with encouraging results, even if long-term… read more here.
Keywords: long term; pixantrone; large cell; diffuse large ... See more keywords
Patients’ decision-making, experiences and preferences regarding pixantrone treatment in relapsed or refractory diffuse large B-cell lymphoma: study protocol for a longitudinal mixed methods study
Sign Up to like & getrecommendations! Published in 2019 at "BMJ Open"
DOI: 10.1136/bmjopen-2018-026505
Abstract: Introduction There is a lot of speculation about why and how patients decide to use invasive treatment in an advanced stage of cancer, but the body of research is limited. The present longitudinal qualitative and… read more here.
Keywords: relapsed refractory; study patients; treatment; study ... See more keywords
Limited efficacy of pixantrone in refractory diffuse large B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2020 at "Oncology Letters"
DOI: 10.3892/ol.2020.11288
Abstract: Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive disease with poor outcomes in patients ineligible for autologous stem cell transplantation. In this setting, novel treatment approaches are urgently required and the innovative… read more here.
Keywords: lymphoma; cell; disease; pixantrone ... See more keywords